 |
Text size:
 |
The CONSERVE Plus Total Hip Resurfacing System is a hip replacement designed for the unique needs of younger patients with degenerative hip disease. The primary purpose of this study is to determine the safety and effectiveness of the CONSERVE Plus system compared to the published results of conventional metal-on-polyethylene total hip replacements.
Edward Sparling, MD is one of eight orthopedic surgeons across the nation to participate as a principal investigator in the clinical trial. Though the initial patient enrollment phase, which began in November 2000, is complete, the FDA recently approved CONSERVE Plus for “continued use access,” which means we may now continue to enroll patients in this study. We will be following all patients for at least two years after surgery.
Donald Roberts, MD, conducts original research on the value of resurfacing the underside of the patella (kneecap) during a Total Knee Replacement. The question is whether a healthy appearing patella, in the presence of an otherwise arthritic knee, should have its surface replaced by a small, polyethylene disk during knee replacement surgery. Currently, both resurfacing the kneecap and not resurfacing it are accepted surgical techniques.
This is a randomized, double-blind study, meaning each patient has an equal chance of being treated with or without patellar resurfacing and both patient and study clinician are unaware which method was used. Patients of both Dr. Donald Roberts, MD, and Dr. T. David Hayes, MD, are participating. Enrollment in this study is complete and patient follow-up will continue for ten years after knee replacement surgery.
T. David Hayes, MD is one of six principals investigating the Rotating Platform knee prosthesis, a device that may potentially provide better function and reduced wear through its advanced technical design. This study, sponsored by DePuy Orthopedics, may help determine if this advanced design will improve wear and function compared to the established standard Total Knee Replacement device we have used for over ten years. Both Total Knee devices are fully FDA approved.
This is a randomized, double-blind study, meaning each patient has an equal chance of being treated with either device and both patient and study clinician are unaware which device was used. Patients of both T. David Hayes, MD and Donald Roberts, MD are invited to enroll in this study. A total of fifty patients will be followed for five years.
Donald Roberts, MD, and T. David Hayes, MD, believe it is important to carefully measure the results of total knee replacement surgery for each patient. They are concerned about how each patient's knee functions before surgery and how the knee replacement improves their quality of life.
Therefore, the doctors monitor the condition and progress of each knee replacement over time. This information enables them to compare progress with other patients who have had the same type of surgery. Each patient is evaluated pre-operatively, then post-operatively at six weeks, 3 months, one and two years, then every other year, culminating in the tenth year following the knee replacement surgery. This research is a collaborative effort with Southwest Washington Medical Center's Rebound Rehabilitation.
Stroke affects 700,000 Americans each year with a stroke occurring about every 45 seconds. One of the leading causes of stroke is untreated carotid artery stenosis. The carotid arteries are the two large blood vessels on either side of the neck and are the main source of blood to the brain. Carotid artery disease occurs when one or both arteries become narrowed or blocked by a buildup of plaque. This disease should be detected and treated as soon as possible to reduce serious risk for stroke.
Carotid artery stenting is a minimally invasive procedure that helps prevent strokes by re-opening the blocked artery. The stent is placed into the narrowed carotid artery and expands to re-open the blocked or narrowed artery thus restoring blood flow to the brain. This procedure is currently used as an alternative to carotid endarterectomy in patients felt to be at high risk during open carotid surgery.
Rebound Neurosurgery is participating in a World Wide Clinical Registry to collect additional clinical outcome data for a Carotid Artery Stenting device already approved by the Food and Drug Administration (FDA).
It is estimated that 80-85% of the population of the United States will experience significant pain as a result of spinal conditions within their lifetime. The cervical spine (neck) is made up of seven bones (vertebrae) with an intervetebral disc between each vertebrae. The disc acts as a shock-absorber between the vertebrae. With normal everyday activities and over time, the spaces between the vertebrae may become narrower. This degenerative process may result in compression of the spinal cord or nerve roots and is often associated with debilitating neck and / or arm pain.
The Secure-C artificial disc was created as an alternative to spinal fusion, the traditional surgical procedure. With spinal fusion, two or more vertebrae are permanently connected so they cannot move except as a single unit. This may alleviate the pain, but has potential disadvantages including loss of motion and flexibility, and possible further degeneration of adjacent discs. In contrast, the Secure-C disc is a device that appears to preserve mobility and function while minimizing the risk of adjacent segment degeneration.
The Secure-C clinical trial is a multicenter, randomized study which involves around 300 subjects enrolled at 20 sites throughout the United States. All four Neurosurgeons at Rebound Neurosurgery have expertise in this alternative surgical procedure and are currently enrolling patients. With over one year of follow-up at this time, the national experience with the Secure-C disc has been very promising.
|
|
|
|
